ClinicalTrials.gg
Active, not recruitingNCT07015983Updated Aug 3, 2026

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

A Phase 2 interventional study of CC-97540 and Fludarabine in Lupus Erythematosus, Systemic and Lupus Nephritis, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Active, not recruiting at 97 sites in 16 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Primary conditionLupus NephritisRegistry: Lupus Erythematosus, SystemicReclassifiedWhy we changed it
Registry
Lupus Erythematosus, Systemic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lupus Nephritis
Why
  1. The study's listed conditions name Lupus Nephritis, a narrower term within Lupus Erythematosus, Systemic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Planned enrollment
35th of 100
89 · median 50
Started
2025
with 13 others
Phase 2
34 of 114
7 open now
Primary completion
2028-05
later than 20 of 49 live
Registered
100th of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 35th largest by planned enrollment of the 100 interventional ones that give a count, is one of 14 that started in 2025, is one of 34 in phase 2, reaches primary completion later than 20 of the 49 other live ones, and was the 100th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.

03

Conditions studied

  • Lupus Erythematosus, Systemic
  • Lupus Nephritis

Browse trials for

Keywords

  • Lupus
  • SLE
  • LN
  • CAR T
  • Cell Therapy
  • CD19 CAR T
  • CD19
  • CD19 NEX-T
  • CD19 NEXT
  • CD19 NEX T
  • Zola-cel
  • Zolacabtagene autoleucel
04

In context

Lupus Nephritis Reclassified

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

This study's planned enrollment of 89 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.

Browse Lupus Nephritis studies →

Lead sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 17 studies on the registry; 12 are open to participants now.

First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb.

Compared within Lupus Nephritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lupus Erythematosus, Systemic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet EULAR/ACR 2019 criteria for SLE.
  • Participants must have an inadequate response to appropriate doses of and ≥ 2 therapies, used for at least 3 months.
  • Participants must have active disease when signing ICF.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have other diseases, conditions, or treatments that may confound interpretation of the effects of CC-97540 in SLE.
  • Uncontrolled or cardiovascular conditions or CNS pathology participants must not have prior history of or lymphoproliferative disease, unless the participant has been free of the disease for ≥ 2 years, except for some non-invasive malignancies.
  • IOCBP who are pregnant, nursing, or breastfeeding, or who intend to become pregnant.
  • Participants must not have prior treatment with CAR T cell therapy, genetically modified T cell therapy, stem cell transplant or organ transplant.
  • Participants must not have received within 6 weeks before LDC (lymphodepleting chemotherapy) administration.
  • Participant must not have inadequate organ function.
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
89 participants (estimated)

Study arms

  • Experimental
    Administration of CC-97540

    Drug: CC-97540 · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • Specified dose on specified days

    Also known as: BMS-986353, Zola-cel, Zolacabtagene autoleucel

  • Specified dose on specified days

  • Specified dose on specified days

07

What researchers measure

Primary outcomes

  1. Proportion of participants achieving drug-free Definition of Remission in Systemic Lupus Erythematosus (DORIS) remission

    Time frame: At month 6

Secondary outcomes

  1. Complete renal response (CRR) for participants with baseline lupus nephritis (LN)

    Time frame: Up to Month 60

  2. Participants with drug-free DORIS remission

    Time frame: Up to month 60

  3. CRR for participants with baseline LN

    Time frame: Up to month 60

  4. Modified CRR for participants with baseline LN

    Time frame: Up to month 60

  5. Number of participants achieving Lupus Low Disease Activity State (LLDAS) with baseline Systemic Lupus Erythematosus Disease Activity Questionnaire (SLEDAI) ≥6

    Time frame: Up to month 60

  6. Number of participants achieving SLE Responder Index (SRI) - 4 with baseline SLEDAI ≥6

    Time frame: Up to month 60

  7. Number of participants with flares as assessed by SLEDAI flare index

    Time frame: Up to month 60

  8. Severity of participants with flares as assessed by SLEDAI flare index

    Time frame: Up to month 60

  9. Change from baseline in proteinuria

    Time frame: Up to month 60

  10. Change from baseline in estimated glomerular filtration rate (eGFR)

    Time frame: Up to month 60

  11. Change from baseline in Systemic Lupus International Collaborating Clinics (SLICC)/ACR (American College of Rheumatology) damage index

    Time frame: Up to month 60

  12. Percentage of participants achieving maintenance of drug-free DORIS remission

    Time frame: Up to month 60

  13. Percentage of participants achieving maintenance of LLDAS

    Time frame: Up to month 60

  14. Percentage of participants achieving maintenance of SRI-4

    Time frame: Up to month 60

  15. Time from first response to loss of response for drug-free DORIS remission

    Time frame: Up to month 60

  16. Time from first response to loss of response for LLDAS

    Time frame: Up to month 60

  17. Time from first response to loss of response for SRI-4

    Time frame: Up to month 60

  18. Time from baseline to first drug-free DORIS remission

    Time frame: Up to month 60

  19. Time from baseline to LLDAS

    Time frame: Up to month 60

  20. Time from baseline to SRI-4

    Time frame: Up to month 60

  21. Duration of drug-free status

    Time frame: Up to month 60

  22. Percentage of participants achieving DORIS remission regardless of drug-free status

    Time frame: Up to month 60

  23. Glucocorticoid used post-infusion for SLE treatment

    Time frame: Up to month 60

  24. Change of serum autoantibodies from baseline

    Time frame: Up to month 60

  25. Change in complement factor (C3 and C4) levels from baseline

    Time frame: Up to month 60

  26. Change from baseline in patient reported outcomes (PRO) as assessed by FACIT-Fatigue

    Time frame: Up to month 60

  27. Change from baseline in PRO as assessed by SF 36 v2 Acute

    Time frame: Up to month 60

  28. Change from baseline in PRO as assessed by EQ-5D-5L

    Time frame: Up to month 60

  29. Change from baseline in PRO as assessed by Patient Global Impression of Severity (PGI-S) Pain

    Time frame: Up to month 60

  30. Change from baseline in PRO as assessed by PGI-S Fatigue

    Time frame: Up to month 60

  31. Patient Global Impression of Change (PGI-C) Pain

    Time frame: Up to month 60

  32. PGI-C Fatigue

    Time frame: Up to month 60

  33. Number of participants with Adverse Events (AEs)

    Time frame: Up to month 60

  34. Number of participants with serious AEs (SAEs)

    Time frame: Up to month 60

  35. Number of participants with AESIs (AEs of Special Interest)

    Time frame: Up to month 60

  36. Number of participants with clinically significant laboratory abnormalities

    Time frame: Up to month 60

08

Study locations

97 sites
09

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2028, 34 months after the start.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 11, 2025
StartActual
Jul 14, 2025
Primary completionEst.
May 17, 2028
CompletionEst.
Jun 15, 2032
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07015983
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jul 14, 2025
Primary completion
May 17, 2028 (estimated)
Completion
Jun 15, 2032 (estimated)
Last update
Aug 3, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolacabtagene autoleucel

Start the discussion